Clinical trials
Resistant Cancer clinical trials
Below are recruiting resistant cancer clinical trials, each written for real people, not researchers. We’re tracking 410 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Birmingham, AlabamaAges 18–100 - NCT07545811RecruitingPhase 1
JANX014 for Advanced Prostate Cancer
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
St Louis, MissouriAges 18 years+ - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT07581184RecruitingPhase 1
Targeted Radioactive Therapy for Advanced Prostate Cancer
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
Irvine, CaliforniaAges 18 years+ - NCT05766371RecruitingPhase 2
Pembrolizumab plus PSMA-targeted therapy for advanced prostate cancer
This Phase 2 trial tests whether adding pembrolizumab to a PSMA-targeted drug can better treat metastatic prostate cancer that has progressed despite hormone-blocking treatments. It may help some people by attacking PSMA-positive cancer spots seen on a special PET scan.
San Francisco, CaliforniaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06783127Recruiting
Olaparib for BRCA-related prostate cancer
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
NaplesAges Any age - NCT07030907RecruitingPhase 1
Testing OPB-101 for platinum-resistant ovarian cancer
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
Detroit, MichiganAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT07739563Recruiting
Exercise for heart health after breast cancer
This study compares two types of exercise programs for women who have completed breast cancer treatment. It aims to see which type of training helps improve heart health and fitness.
Pittsburgh, PennsylvaniaAges 20–89 - NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT06738303RecruitingPhase 2
Cabazitaxel with or without carboplatin vs lutetium PSMA for prostate cancer
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Cleveland, OhioAges 19 years+ - NCT06190899RecruitingPhase 1/Phase 2
Testing gedatolisib plus darolutamide in advanced prostate cancer
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Los Angeles, CaliforniaAges 18 years+ - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Irving, TexasAges 18 years+
Hear when a new Resistant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistant cancer?
- Yes. Clin2 currently lists 410 recruiting resistant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Platinum-resistant Ovarian Cancer
- Castrate Resistant Prostate Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.